The aim of this study was to test whether TAZ abundance is associated with survival in rhabdomyosarcoma and to characterize the cancer‐specific functions of TAZ in myoblasts and human ERMS cells, to identify TAZ as either an oncogene and YAP agonist or as a tumour suppressor. The gene discussed is YAP1; the disease is neoplasm.